A synbiotic supplement for inflammation and oxidative stress and lipid abnormalities in hemodialysis patients
A synbiotic supplement for inflammation and oxidative stress and lipid abnormalities in hemodialysis patients
复制标题
DOI：
10.1111/hdi.12748
复制
发表时间：
2019-04-01
影响因子：
1.3
通讯作者：
Miri, Mohammad
中科院分区：
文献类型：
--
作者：
Kooshki, Akram;Tofighiyan, Tahereh;Miri, Mohammad
简介：血液透析患者心血管疾病最重要的危险因素包括高浓度的血清炎症标志物、血脂和氧化应激。本研究旨在探讨合生素补充剂对血液透析患者血清系统性炎症、氧化应激标志物和血脂的影响。方法：50例血液透析患者随机分为合生元组和安慰剂组。合生元组每天服用2片合生元补充剂（100毫克）、凝结乳杆菌和低聚果糖，持续8周;而安慰剂组服用外观相似的安慰剂。在研究开始和结束时，禁食12- 14小时后采集5 mL血液。调查结果：合生元组治疗结束时血清C-反应蛋白（hs-CRP）和丙二醛（MDA）的平均值较治疗开始时显著降低（P=0.01）。与安慰剂组的变化相比，这种降低是显著的（P=0.01）。与安慰剂组相比，合生素补充剂还降低了血清总胆固醇（P=0.001）和低密度脂蛋白胆固醇（LDL-c; P=0.001）。讨论内容：合生素补充剂可改善血液透析患者的血清hs-CRP和MDA、总胆固醇和LDL-c，这些都是已知的心血管疾病风险因素。
Introduction: Among the most important risk factors for cardiovascular disease in hemodialysis patients are high concentrations of serum inflammation markers, lipid profiles, and oxidative stress. The present study aimed to investigate the effects of a synbiotic supplement on serum systemic inflammation, oxidative stress markers, and lipid profile in hemodialysis patients. Methods: Fifty hemodialysis patients were randomly allocated to synbiotic and placebo groups. The synbiotic group received 2 tablets per day of a synbiotic supplement (100mg) Lactobacillus coagulans and fructo-oligosaccharides for 8weeks; whereas the placebo group received a similar appearing placebo. At the beginning and end of the study, 5mL blood was taken after 12-14hours of fasting. Findings: Mean values of serum C-reactive protein (hs-CRP) and malondialdehyde (MDA) significantly decreased in the synbiotic group at the end compared to the beginning of the study (P=0.01). This reduction was significant in comparison with changes in the placebo group (P=0.01). The synbiotic supplement also reduced serum total cholesterol (P=0.001) and low-density lipoprotein cholesterol (LDL-c; P=0.001) compared to the placebo group. Discussion: The synbiotic supplement used improves serum hs-CRP and MDA, total cholesterol and LDL-c in hemodialysis patients, which are known risk factors for cardiovascular disease.